Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mavorixafor
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Recipient : X4 Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
X4 Pharma, Taiba Rare Ink Xolremdi Deal for WHIM in Middle East
Details : Under the agreement, Taiba will be responsible for the distribution and commercialization of Xolremdi (mavorixafor), an oral, once-daily treatment for WHIM syndrome in MENA region.
Product Name : Xolremdi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : Mavorixafor
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Recipient : X4 Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Varnimcabtagene Autoleucel
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Immuneel Therapeutics
Deal Size : $12.0 million
Deal Type : Financing
Taiba Makes Strategic Investment in Immuneel Therapeutics to Advance CAR T-cell Research
Details : The intended to advance CAR T-cell research development of Phase 2 trial for CD19 CAR-T IMN-003A (varnimcabtagene autoleucel) targeting B-cell malignancies, including leukemia and lymphoma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : Varnimcabtagene Autoleucel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Immuneel Therapeutics
Deal Size : $12.0 million
Deal Type : Financing
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Aspargo Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Aspargo Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Insmed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory.
Product Name : Arikayce
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 14, 2021
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Insmed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Patisiran
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : The distribution agreement is focused on both ONPATTRO® and GIVLAARI®, the first-ever commercialized RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1.
Product Name : Onpattro
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : Patisiran
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Elevar Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North...
Product Name : Apealea
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 10, 2020
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Elevar Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement